Sibutramine Hydrochloride agent for the treatment of obesity Central action. The mechanism of action is associated with selective inhibition of the reuptake of serotonin and norepinephrine, to a lesser extent dopamine. Accelerates the onset and prolong satiety, which leads to reduction of food intake. Increases energy expenditure by stimulating thermogenesis mediated by the activation of β3-adrenoceptor. Acts on both sides of the energy balance and helps reduce body weight.
Sibutramine and its metabolites do not release monoamines, and are not MAO inhibitors, have no affinity for serotonergic, adrenergic, dopaminergic, muscarinic, histamine, benzodiazepine and NMDA receptors.As part of supporting the complex therapy of patients with overweight in alimentary obesity with a body mass index of 30 kg/m2 or more, with alimentary obesity with a body mass index of 27 kg/m2 or more if there are other risk factors caused by excessive body weight, including diabetes mellitus type 2 (insulin-independent) or hyperlipidemia.